Oppenheimer's decision to downgrade the stock rating reflects the uncertainty surrounding the future of the BEACON trial and the potential impact on Pliant Therapeutics' prospects. The analysts ...

Oppenheimer analysts downgraded Pliant Therapeutics stock from Outperform to Perform, following a significant development ...

Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...

Annovis Bio's CEO to present at Oppenheimer's conference, discussing Phase 3 trial progress and NDA initiatives for buntanetap. Annovis Bio Inc. has announced that its CEO, Dr. Maria Maccecchini ...

Oppenheimer analyst Jeff Jones downgraded Pliant Therapeutics (PLRX) to Perform from Outperform without a price target after the company ...

Oppenheimer raised the firm’s price target on Shopify (SHOP) to $150 from $130 and keeps an Outperform rating on the shares. The company’s ...

Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and ...